Foundation Medicine Inc (NASDAQ:FMI) SVP Robert W. Hesslein sold 1,864 shares of Foundation Medicine stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $64.00, for a total transaction of $119,296.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Shares of Foundation Medicine Inc (NASDAQ:FMI) traded up $1.98 during trading hours on Thursday, reaching $65.03. 103,832 shares of the company traded hands, compared to its average volume of 332,550. The stock has a market capitalization of $2,350.00, a PE ratio of -14.55 and a beta of -0.01. Foundation Medicine Inc has a 12 month low of $17.50 and a 12 month high of $70.75. The company has a current ratio of 2.24, a quick ratio of 2.03 and a debt-to-equity ratio of 0.47.
Foundation Medicine (NASDAQ:FMI) last issued its quarterly earnings data on Wednesday, November 1st. The company reported ($0.90) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.16. The company had revenue of $42.66 million during the quarter, compared to analysts’ expectations of $37.99 million. Foundation Medicine had a negative net margin of 119.69% and a negative return on equity of 143.18%. Foundation Medicine’s revenue for the quarter was up 45.0% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.90) earnings per share. equities analysts anticipate that Foundation Medicine Inc will post -4.44 earnings per share for the current year.
A number of large investors have recently modified their holdings of FMI. Lord Abbett & CO. LLC grew its stake in Foundation Medicine by 146.0% during the second quarter. Lord Abbett & CO. LLC now owns 579,225 shares of the company’s stock valued at $23,024,000 after acquiring an additional 343,770 shares in the last quarter. Peregrine Capital Management LLC bought a new stake in Foundation Medicine during the third quarter valued at approximately $13,299,000. State Street Corp lifted its position in Foundation Medicine by 124.2% during the second quarter. State Street Corp now owns 526,775 shares of the company’s stock valued at $20,947,000 after purchasing an additional 291,815 shares during the last quarter. Baillie Gifford & Co. lifted its position in Foundation Medicine by 42.0% during the second quarter. Baillie Gifford & Co. now owns 248,300 shares of the company’s stock valued at $9,870,000 after purchasing an additional 73,500 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in Foundation Medicine by 8.2% during the second quarter. Vanguard Group Inc. now owns 631,339 shares of the company’s stock valued at $25,096,000 after purchasing an additional 47,843 shares during the last quarter. 32.68% of the stock is owned by institutional investors.
Several brokerages recently commented on FMI. BidaskClub raised shares of Foundation Medicine from a “hold” rating to a “buy” rating in a research note on Wednesday, December 27th. Zacks Investment Research cut shares of Foundation Medicine from a “buy” rating to a “sell” rating in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $45.33.
Foundation Medicine Company Profile
Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.
Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with MarketBeat.com's FREE daily email newsletter.